|
| Tuesday, 12 July 2016, 06:00 HKT/SGT | |
| |  | |
Source: TrialWire | |
|
|
|
ADELAIDE, AUS, July 12, 2016 - (ACN Newswire) - Hepatitis B is a virus that is spread through contact with the blood or bodily fluids of an infected person.
In Australia, approximately 225,000 people are living with chronic Hepatitis B, which is defined as having had the infection for longer than six months. However, according to Hepatitis Australia, nearly half of those living with chronic Hepatitis B in Australia are undiagnosed.
A clinical trial is now open for people who have been diagnosed with chronic Hepatitis B Virus (HBV) infection, who have not had treatment for this condition in the last 2 years. Other entry requirements apply.
The purpose of this research study is to assess the effectiveness and safety of a novel medicine for the treatment of patients with chronic Hepatitis B.
The study will assess the effects of the study medicine alone or in combination with other Hepatitis B treatments such as entecavir and pegylated interferon alpha 2a therapy.
Participating clinics include leading hospitals and medical centres. Patients will need to agree to participate in the study for approximately 96 weeks, involving 31 clinic visits and a preliminary screening period of up to 60 days.
Travel expenses to clinic appointments will be reimbursed upon presentation of receipts or appropriate documentation.
Patients will need to provide written informed consent to enter into the study. Clinic staff will discuss any other factors that may determine eligibility. If you think you might be eligible, please click below to find your nearest participating clinic.
For general information, please visit http://newscaster.thetrialwire.com/hepb-clinical-trial-au/.
To contact, please visit http://bit.ly/HepB-Clinical-TrialAUNZ.
Contact your nearest participating clinic to book a medical screening appointment. The study can enroll up to 96 people. All study medication, medical appointments, and tests are free of charge.
This clinical trial has been reviewed and approved in accordance with the Australian Human Research Ethics Committee process.
Contact:
Team Trial-Wire
Level 6/69 Reservoir Street
Surry Hills NSW 2010 Australia
AU +61 2 8218 2144
Email: team@dmgpr.com
http://www.trial-wire.com/
Topic: Clinical Trial Results
Source: TrialWire
Sectors: Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
